The healthcare sector has led all S&P 500 sectors with a 13.10% gain over the past three months, despite lagging year-to-date. Major pharmaceutical companies Eli Lilly, Johnson & Johnson, and AbbVie offer a mix of growth and income, with strong recent earnings and dividend increases. Johnson & Johnson stands out with a 24.11% YTD gain and 64 years of consecutive dividend raises. Investors should watch for second-half earnings momentum and FDA approvals as key drivers for continued sector strength.
Nxera Pharma announced a net profit of JPY 1,591 million (US$10.1 million) for Q2 2026, reversing a prior loss due to multiple milestone payments from partners like Neurocrine, AbbVie, and Lilly. The company progressed regulatory approvals and commer...
Eli Lilly and Novo Nordisk both beat Q2 estimates and raised their full-year outlooks, but investors favored Lilly, boosting its shares while punishing Novo. Lilly leads the obesity drug market with a 60.9% U.S. share, driven by strong sales of Mounj...
Eli Lilly reported strong Q2 results with robust revenue growth led by key drugs Mounjaro and Zepbound. The company raised its 2026 revenue guidance to $85–87 billion, supported by volume gains despite price declines, and expects continued margin exp...
Eli Lilly reported a 48% year-on-year revenue increase to $22.97 billion, driven by strong sales of GLP-1 drugs Mounjaro and Zepbound, which make up about 65% of total revenue. The company raised its 2026 revenue guidance to $85 billion–$87 billion, ...
